The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

All physicians are faced with the challenge of how to help patients with no approved therapies for their diseases. What are ...

The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

NYU Langone Health in New York City reportedly cancelled the appointments of two transgender children scheduled to receive ...

The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to Actemra, developed by South ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.